OBJECTIVE: To determine whether CA-125 velocity is a statistically significant predictor of ovarian cancer and develop a classification rule to screen for ovarian cancer. METHODS: In the ovarian component of the PLCO cancer screening trial, 28,038 women aged 55-74 had at least two CA-125 screening tests. Ovarian cancer was diagnosed in 72 (0.26%) women. A multiple logistic regression model was developed to evaluate CA-125 velocity and other related covariates as predictors of ovarian cancer. Predictive accuracy was assessed by the concordance index and measures of discrimination and calibration while the fit of the model was assessed by the Hosmer and Lemeshow's goodness-of-fit χ(2)test. RESULTS:CA-125 velocity decreased as the number of CA-125 measurements increased but was unaffected by age at baseline screen and family history of ovarian cancer. The average velocity (19.749U/ml per month) of the cancer group was more than 500 times the average velocity (0.035U/ml per month) of the non-cancer group. CONCLUSION: Among six covariates used in the model, CA-125 velocity and time intervals between baseline and second to last screening test and between last two screening tests were statistically significant predictors of ovarian cancer. The chance of having ovarian cancer increased as velocity increased, and the chance decreased when the time intervals between baseline and the second to last screening test and between last two screening tests of an individual increased. Copyright Â
RCT Entities:
OBJECTIVE: To determine whether CA-125 velocity is a statistically significant predictor of ovarian cancer and develop a classification rule to screen for ovarian cancer. METHODS: In the ovarian component of the PLCO cancer screening trial, 28,038 women aged 55-74 had at least two CA-125 screening tests. Ovarian cancer was diagnosed in 72 (0.26%) women. A multiple logistic regression model was developed to evaluate CA-125 velocity and other related covariates as predictors of ovarian cancer. Predictive accuracy was assessed by the concordance index and measures of discrimination and calibration while the fit of the model was assessed by the Hosmer and Lemeshow's goodness-of-fit χ(2)test. RESULTS:CA-125 velocity decreased as the number of CA-125 measurements increased but was unaffected by age at baseline screen and family history of ovarian cancer. The average velocity (19.749U/ml per month) of the cancer group was more than 500 times the average velocity (0.035U/ml per month) of the non-cancer group. CONCLUSION: Among six covariates used in the model, CA-125 velocity and time intervals between baseline and second to last screening test and between last two screening tests were statistically significant predictors of ovarian cancer. The chance of having ovarian cancer increased as velocity increased, and the chance decreased when the time intervals between baseline and the second to last screening test and between last two screening tests of an individual increased. Copyright Â
Authors: E W Steyerberg; F E Harrell; G J Borsboom; M J Eijkemans; Y Vergouwe; J D Habbema Journal: J Clin Epidemiol Date: 2001-08 Impact factor: 6.437
Authors: H H Gallion; J E Hunter; J R van Nagell; H E Averette; J M Cain; L J Copeland; R V Higgins; N Husseinzadeh; W A Nahhas; E E Partridge Journal: Gynecol Oncol Date: 1992-07 Impact factor: 5.482
Authors: P C Prorok; G L Andriole; R S Bresalier; S S Buys; D Chia; E D Crawford; R Fogel; E P Gelmann; F Gilbert; M A Hasson; R B Hayes; C C Johnson; J S Mandel; A Oberman; B O'Brien; M M Oken; S Rafla; D Reding; W Rutt; J L Weissfeld; L Yokochi; J K Gohagan Journal: Control Clin Trials Date: 2000-12
Authors: James L Wilder; Edward Pavlik; John M Straughn; Tyler Kirby; Robert V Higgins; Paul D DePriest; Frederick R Ueland; Richard J Kryscio; Ronald J Whitley; John van Nagell Journal: Gynecol Oncol Date: 2003-05 Impact factor: 5.482
Authors: Sinead A Noonan; Tejas Patil; Dexiang Gao; Gentry G King; Jessica R Thibault; Xian Lu; Paul A Bunn; Robert C Doebele; W Thomas Purcell; Anna E Barón; D Ross Camidge Journal: J Thorac Oncol Date: 2017-08-24 Impact factor: 15.609
Authors: Usha Menon; Andy Ryan; Jatinderpal Kalsi; Aleksandra Gentry-Maharaj; Anne Dawnay; Mariam Habib; Sophia Apostolidou; Naveena Singh; Elizabeth Benjamin; Matthew Burnell; Susan Davies; Aarti Sharma; Richard Gunu; Keith Godfrey; Alberto Lopes; David Oram; Jonathan Herod; Karin Williamson; Mourad W Seif; Howard Jenkins; Tim Mould; Robert Woolas; John B Murdoch; Stephen Dobbs; Nazar N Amso; Simon Leeson; Derek Cruickshank; Ian Scott; Lesley Fallowfield; Martin Widschwendter; Karina Reynolds; Alistair McGuire; Stuart Campbell; Mahesh Parmar; Steven J Skates; Ian Jacobs Journal: J Clin Oncol Date: 2015-05-11 Impact factor: 44.544
Authors: Azahara Palomar Muñoz; José Manuel Cordero García; Mª Del Prado Talavera Rubio; Ana Mª García Vicente; Francisco José Pena Pardo; Germán Andrés Jiménez Londoño; Ángel Soriano Castrejón; Enrique Aranda Aguilar Journal: Medicine (Baltimore) Date: 2018-04 Impact factor: 1.889
Authors: Parsa Charkhchi; Cezary Cybulski; Jacek Gronwald; Fabian Oliver Wong; Steven A Narod; Mohammad R Akbari Journal: Cancers (Basel) Date: 2020-12-11 Impact factor: 6.639